PBP1510 + gemcitabine

**PBP1510 + gemcitabine** is an investigational combination therapy under clinical evaluation for advanced or metastatic pancreatic adenocarcinoma that has relapsed or is refractory to at least one prior line of therapy. PBP1510 (also called Ulenistamab) is a first-in-class, humanized IgG1 monoclonal antibody targeting Pancreatic Adenocarcinoma Upregulated Factor (PAUF), a tumor-specific protein frequently overexpressed in pancreatic cancer. PAUF promotes proliferation, invasion, metastasis, and contributes to drug resistance. By neutralizing PAUF, PBP1510 aims to suppress cancer growth, migration, and chemoresistance. Gemcitabine is a nucleoside analog cytotoxic chemotherapy agent commonly used as standard care in pancreatic cancer. The combination aims to provide synergistic anti-tumor activity through complementary mechanisms: immune-targeting and cytotoxicity. Clinical evaluation is ongoing in a global Phase 1/2a trial, focusing on safety, tolerability, and efficacy in patients with advanced/metastatic pancreatic cancer[1][2][3][4][7].

Other names

anti-PAUF monoclonal antibody + gemcitabine